Profile data is unavailable for this security.
About the company
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
- Revenue in USD (TTM)8.96m
- Net income in USD-9.63m
- Incorporated1986
- Employees29.00
- LocationPalatin Technologies Inc4-B Cedar Brook DriveCedar Brook Corporate CenterCRANBURY 08512United StatesUSA
- Phone+1 (609) 495-2200
- Fax+1 (609) 495-2202
- Websitehttps://www.palatin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.56m | 37.00 | -- | 2.58 | -- | 395.15 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| CervoMed Inc | 6.16m | -25.58m | 35.99m | 15.00 | -- | 1.38 | -- | 5.84 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.24m | 24.00 | -- | 3.49 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.53m | 64.00 | -- | -- | -- | 1.15 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 36.86m | 52.00 | -- | 10.01 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 37.15m | 10.00 | -- | 1.33 | -- | 9.23 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 37.60m | 14.00 | -- | 1.63 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 37.78m | 64.00 | -- | 3.26 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 38.19m | 16.00 | -- | 2.97 | -- | 47.86 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 38.34m | 46.00 | -- | 0.5772 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 38.63m | 26.00 | -- | 2.21 | -- | 36.11 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.18m | 38.75m | 13.00 | -- | 0.7783 | -- | -- | -3.52 | -3.52 | 0.00 | 5.78 | 0.00 | -- | -- | 0.00 | -43.90 | -26.93 | -48.89 | -29.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.25 | -- | 20.02 | -- |
| Palatin Technologies Inc | 8.96m | -9.63m | 39.79m | 29.00 | -- | 3.44 | -- | 4.44 | -10.46 | -10.46 | 7.19 | 6.53 | 0.8062 | -- | -- | 309,089.30 | -86.59 | -79.95 | -303.40 | -118.70 | 0.00 | 91.70 | -107.41 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 41.93m | 2.00 | -- | -- | -- | 1,677.29 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Veru Inc | 0.00 | -19.20m | 42.05m | 20.00 | -- | 1.13 | -- | -- | -1.21 | -1.20 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -43.95 | -47.51 | -51.96 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 42.86m | 70.00 | -- | 0.5967 | -- | 16.20 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
Data as of Mar 03 2026. Currency figures normalised to Palatin Technologies Inc's reporting currency: US Dollar USD
46.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Driehaus Capital Management LLCas of 31 Dec 2025 | 166.71k | 9.79% |
| Logos Global Management LPas of 31 Dec 2025 | 140.00k | 8.22% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 140.00k | 8.22% |
| Point72 Asset Management LPas of 31 Dec 2025 | 115.00k | 6.75% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 70.00k | 4.11% |
| RA Capital Management LPas of 31 Dec 2025 | 70.00k | 4.11% |
| Superstring Capital Management LPas of 31 Dec 2025 | 33.97k | 2.00% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 27.05k | 1.59% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 18.98k | 1.12% |
| Geode Capital Management LLCas of 31 Dec 2025 | 17.71k | 1.04% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
